Gut microbiome determines efficacy of anti-diabetes drugs: Study

Image
IANS New York
Last Updated : Dec 13 2018 | 4:10 PM IST

Ever wondered why orally-administered drugs for diabetes work for some people but not for others? According to researchers, including one of Indian origin, bacteria that make up the gut microbiome might be the reason.

The study, from the Wake Forest University in the US, examined how gut bacteria either enhanced or inhibited a drug's effectiveness.

"Certain drugs work fine when given intravenously and go directly to the circulation, but when they are taken orally and pass through the gut, they do not work," said Hariom Yadav, Assistant Professor from the varsity.

"Conversely, metformin, a commonly used anti-diabetes drug, works best when given orally but does not work when given through an IV," he added.

Examining interactions between the most commonly prescribed anti-diabetic drugs with the microbiome, the team found that before being absorbed into the bloodstream, many orally-administered drugs are processed by intestinal microbial enzymes.

As a result, the gut microbiome influences the metabolism of the drugs, thereby affecting patients' responses, Yadav said, in the paper published in the journal EBioMedicine.

"Our review showed that the metabolic capacity of a patient's microbiome could influence the absorption and function of these drugs by making them pharmacologically active, inactive or even toxic," Yadav said.

"We believe that differences in an individual's microbiome help explain why drugs will show a 90 or 50 per cent optimum efficacy, but never 100 per cent," he noted.

Importantly, modulation of the gut microbiome by drugs may represent a target to improve, modify or reverse the effectiveness of current medications for Type-2 diabetes, the researchers noted.

--IANS

pb/rt/mag/bg

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Dec 13 2018 | 3:56 PM IST

Next Story